Funding

For many startups, non-dilutive funding-money that does not require giving up equity-is the first source of capital.

Government Grants and Programs:

• United States: NIH, SBIR (Small Business Innovation Research), and STTR (Small Business Technology Transfer) grants provide early-stage support. BARDA offers funding for devices addressing public health emergencies.
• Europe: Horizon Europe, EIC Accelerator, and national innovation funds (such as Innovate UK) provide grants for MedTech innovation.
• Canada: IRAP
• Australia: Biomedical Translation Fund
• Singapore: A*STAR programs

Advantages:

• No equity dilution.

Limitations:

• Highly competitive with low success rates.
• Applications and project management are time-consuming and usually require dedicated FTE (Full-Time Equivalent employee).
• Funding cycles and funded activities may not align with industry best practices and commercial timelines.

Competitions and Challenges:

Innovation competitions hosted by corporates, accelerators, or foundations offer funding, in-kind support, or pilot opportunities. While smaller in amount, these can significantly boost visibility and provide a path to longer-term corporate partnerships or venture financing.

After initial non-dilutive funding, many startups turn to friends and family or angel investors, who invest small sums of money in exchange for a share of ownership, known as equity.

• Friends and Family: Often the earliest outside source of capital, these investments are informal but can carry risks of personal relationship strain if the venture struggles.
• Angel Investors: Angels are typically high-net-worth individuals who invest their own money in exchange for equity. Many individuals have backgrounds in healthcare and can offer mentorship and valuable connections. Angels usually participate in the seed stage, with investment sizes ranging from $50,000 to $1 million.
• Family Offices and High-Net-Worth Individuals: Family offices, managing wealth for ultra-high-net-worth families, are increasingly active in MedTech investing. They often have longer time horizons than traditional VCs, making them suitable for devices with longer regulatory and adoption cycles.
• Patient-Investor Communities: Patients and advocacy groups are increasingly becoming active in funding innovations that directly impact their care.

Advantages:

• Quick decision-making compared to institutions.
• Flexible deal structures.
• Access to experienced business or industry mentors and valuable networks.
• Can be patient capital, depending on the investor.

Limitations:

• Limited follow-on capital compared to institutional investors.
• Potential misalignment if investors lack MedTech industry expertise.
• Investment decisions may be idiosyncratic.
• Less visibility compared to VCs.

Venture capital (VC) remains one of the most important financing sources for scaling MedTech innovation. There are different types of VCs that engage in financing medical technology companies:

• Specialist funds: Dedicated to healthcare/MedTech, such as Sofinnova, Versant Ventures, and Wellington Partners.
• Generalist VCs with healthcare teams: Larger funds that invest across sectors but maintain a healthcare focus.
• Corporate VCs: Strategic corporate investors like Medtronic Ventures, Johnson & Johnson Development Corporation, and Abbott Ventures.

Advantages:

• Large pools of capital for scaling.
• Strategic advice and board-level support.
• Access to networks, partnerships, and future investors.

Limitations:

• Dilution of ownership.
• Pressure for high growth and exit (IPO or acquisition).
• Selective criteria: many strong MedTech startups fail to secure VC funding due to perceived risk or long timelines.

Many medical device startups seek strategic partnerships with larger industry players.

Advantages:

• Non-dilutive or partially dilutive, depending on partnership type and structure.
• Reduces risk by leveraging established infrastructure, resources and industry expertise.
• Provides credibility and accelerates market access.

Limitations:

• May reduce autonomy, depending on the nature of the partnership.
• Negotiations can be lengthy and complex.
• Corporates may push for exclusivity, limiting other opportunities.

Debt financing can be attractive for companies that want to avoid dilution, though it requires strong financial discipline. For tech and MedTech startups, debt financing takes several forms, ranging from “soft” quasi-equity instruments to more traditional debt. Each has different implications for cash flow, ownership, and investor expectations. The types of debt financing available also change depending on the country and the risk appetite of lenders.

Bank & Institutional Debt:

• Term Loans: Fixed repayment schedule, often secured against assets (hard for early tech startups without collateral).
• Working Capital Loans / Lines of Credit: Flexible drawdown for managing cash flow; typically tied to revenues, receivables, or inventory.
• Revolving Credit Facilities: Renewable credit line, useful for scaling companies with predictable cash inflows.

** Venture Debt:**

• Offered by specialised lenders alongside or after equity rounds.
• Typically structured as interest + warrant coverage (lender gets the right to buy equity at a set price).
• Benefits: non-dilutive (to a point), extends runway between equity rounds.
• Risks: Requires strong VC backing; often costly relative to bank debt.

Convertible Instruments:

• Convertible Notes (Convertible Loans): Debt that converts into equity at a future financing round, usually with a discount or valuation cap.
• SAFE (Simple Agreement for Future Equity): Not strictly debt, but similar in spirit: an advance that converts into equity on defined terms.

Quasi-Equity / Hybrid Debt:

• Soft Loans: Below-market interest or favourable repayment terms, often backed by governments, development banks, or social impact funds. Sometimes, conditional on achieving milestones (e.g., R&D completion).
• Revenue-Based Financing (RBF): Repayments linked to a percentage of future revenues until a cap or multiple of principal is repaid. No dilution, flexible with performance.
• Royalty Financing: Similar to RBF, but linked to product sales rather than overall revenues.

Public & Development Programs:

• Government Grants with Repayable Components: Some grants are structured as forgivable or contingent loans if milestones aren’t met.
• Development Bank Loans: Often favourable terms for startups in priority sectors (digital, MedTech, green tech).

Advantages:

• Preserves equity.
• Provides bridge financing between equity rounds.
• Can extend runway during critical phases.

Limitations:

• Requires collateral or revenue history.
• Interest and repayment obligations create financial pressure.
• Not suitable for very early-stage companies.

For more mature MedTech companies, public markets can provide significant growth capital.

IPOs (Initial Public Offerings):

Listing on exchanges such as NASDAQ, NYSE, or Euronext provides access to large pools of institutional and retail investor capital. IPOs are generally pursued by companies with products on-market with proven commercial traction and revenue momentum. However, it is also possible for companies to IPO before launching their first product, provided that their development activities are supported by strong clinical or technical evidence and a clear commercialisation pathway is in place.

Advantages:

• Access to significant capital to fund resource-intensive activities such as later-stage development, commercialisation, or international expansion.
• Enhanced visibility and credibility with customers, partners, and regulators.
• Liquidity for early investors and employees through secondary sales.
• Acquisition currency: publicly listed shares can be used to acquire other businesses or technologies.

Limitations:

• High costs of underwriting, legal, and ongoing compliance with securities regulations.
• Quarterly reporting pressures, which can conflict with the long development cycles typical in tech and health tech.
• Disclosure requirements may reveal sensitive information to competitors.
• Market volatility may depress valuations or make IPO timing difficult.

SPACs (Special Purpose Acquisition Companies):

SPAC mergers surged in popularity during 2020-2021 as a faster route to public markets, though activity has since cooled. In a SPAC deal, a listed “blank check” company raises money from investors, then merges with a private company to take it public.

Advantages:

• Quicker route to public listing compared to a traditional IPO, with fewer regulatory hurdles upfront.
• Access to substantial funding, often coupled with PIPE (private investment in public equity) financing.
• Negotiated valuations provide more certainty than volatile IPO pricing.
• Liquidity for early investors and employees sooner than in private markets.
• Increased visibility and credibility from being a listed company.

Limitations:

• High transaction costs and dilution from SPAC sponsor promote shares.
• Regulatory scrutiny has increased after concerns about overly optimistic projections.
• Market scepticism: post-merger SPACs have often underperformed, hurting valuations.
• Integration and disclosure requirements remain complex after the merger.
• Pressure to meet short-term investor expectations despite long product development cycles.

With the rise of digital platforms, alternative financing options are emerging for healthcare products.

• Equity crowdfunding: Platforms like Crowdcube, SeedInvest, and OurCrowd allow startups to raise equity capital from a broad pool of investors.
• Donation-Based and Reward-Based Crowdfunding: Platforms like Kickstarter or Indiegogo can be effective for direct-to-consumer products that don’t require long development timelines.

Crowdfunding is beneficial for consumer-facing medical technology devices or digital health solutions that engage patients and consumers directly.

Limitations:

• May not provide sufficient capital for high-cost development activities.
• Requires strong storytelling and marketing.
• Equity crowdfunding can complicate cap tables.

Some investors finance innovation by securing rights to future royalties or intellectual property (IP) revenue streams rather than taking equity or traditional debt positions. This model is particularly relevant for tech, life sciences, and MedTech startups where intellectual property and licensing deals form the core value proposition.

The investor provides upfront capital to the startup and receives a share of future revenues, often linked to product sales, licensing deals, or milestone payments. The arrangement can be structured as:

• Royalty Financing: repayments tied to a percentage of sales or revenue until an agreed multiple of the original investment is reached.
• IP-Backed Loans: debt secured against patents, trademarks, or software IP, with IP as collateral.
• Securitisation of Royalties: packaging predictable royalty streams into financial instruments to raise larger amounts of capital (common in pharma/biotech).

Advantages:

• Non-dilutive.
• Flexible repayments that scale with revenue, easing the burden during early commercialisation.
• Leverages intangible assets, allowing startups to unlock value from patents or software without immediate sales traction.
• Attractive to investors looking for predictable cash flows tied to product adoption.

Limitations:

• Revenue commitment reduces future cash flow, which can limit reinvestment in growth.
• Valuing the worth of early-stage patents or royalty streams is subjective and can disadvantage startups.
• Potential loss of IP rights if repayment terms are not met.
• Best suited to companies with strong IP protection and clear licensing potential, but less useful for early startups without validated markets.

Revenue-based financing is a form of growth capital where investors provide upfront funding to a startup in exchange for a fixed percentage of the company’s future revenues. Instead of fixed interest payments (as in debt) or equity dilution (as in venture capital), repayments rise and fall with the company’s performance until a pre-agreed total (usually a multiple of the original investment) has been repaid. RBF is best suited for startups that:

• Have predictable or recurring revenues (e.g., SaaS, subscription-based tech, e-commerce with repeat sales).
• Are scaling, not pre-revenue-the model only works if there’s already meaningful cash flow.
• Prefer to avoid dilution, keeping founders’ equity intact.
• Want flexible repayment terms tied to performance, avoiding the cash strain of fixed loan repayments.
• Need growth capital for marketing, sales expansion, or working capital, rather than long-term R&D (where cash flow may be years away).
• Faster process to arrange than equity, often requiring less due diligence than venture capital or bank loans.

Limitations:

• Total repayment cost can be high (multiples of principal).
• Reduces free cash flow available for reinvestment.
• Investors usually cap the amount to a modest percentage of ARR/MRR, so it may not fund very large-scale initiatives.

A growing pool of ESG-driven (Environmental, Social, and Governance) investors is entering the MedTech sector, particularly in areas that address global health inequities. These investors prioritise not only financial returns but also measurable social and environmental outcomes, aligning with the broader shift toward sustainable finance. The key drivers for this type of investing are:

• Global health priorities: Access to affordable diagnostics, treatment, and digital health solutions in underserved markets.
• Climate and healthcare linkages: Growing awareness of the environmental footprint of healthcare (e.g., single-use devices, supply chain emissions).
• Regulatory and reporting pressures: Increasing requirements for ESG disclosures and sustainable business practices.

Startups can access this capital through several tailored financing instruments:

• Grants: Non-dilutive funding offered by philanthropic funds or accelerators addressing specific challenges (e.g. Gates Foundation). These funds can support projects that would be difficult to finance through traditional schemes, but often come with stringent conditions that can affect future opportunities.
• Soft Loans and Concessional Debt: Provided by development banks, philanthropic funds, or government programs. Often feature low interest rates, flexible repayment schedules, or milestone-based forgiveness.
• Blended Finance: Combines concessional capital (from impact investors or DFIs) with commercial investment. Reduces risk for commercial investors, enabling larger investments in underserved or high-risk markets.
• Outcome-Based Financing (Social Impact Bonds): Investors provide upfront capital; repayments are linked to measurable health outcomes (e.g., number of patients screened, improved vaccination rates) to align incentives for both investors and healthcare providers.
• Equity Impact Funds: Target startups that generate both financial returns and measurable social/environmental impact. Investors often provide patient capital, tolerating longer development cycles and supporting global expansion.

Advantages:

• Access to patient, mission-aligned capital that may tolerate longer development cycles and lower valuations.
• Enhanced brand reputation and credibility with payers, regulators, and global health stakeholders.
• Opportunity to differentiate in competitive markets by embedding sustainability and equity into the business model.

Limitations:

• ESG investors often require robust impact measurement and reporting, which can add overhead.
• Funding may be earmarked for specific geographies or patient populations, limiting flexibility.
• Not all MedTech business models fit neatly into ESG frameworks, making it harder for some startups to attract impact investors.